Three receptors. Maximum metabolic reach.
Where semaglutide targets one incretin receptor and tirzepatide targets two, retatrutide targets three: GLP-1, GIP, and glucagon. The addition of glucagon receptor agonism is what fundamentally distinguishes it from the prior generation.
Glucagon is typically thought of as a glucose-raising hormone — the counter-regulatory signal to insulin. But glucagon receptor activation in the context of GLP-1 co-stimulation produces different effects: it increases energy expenditure, promotes fat oxidation (particularly in the liver), and enhances metabolic rate. The co-activation prevents the hypoglycemic effect glucagon alone would not cause.
The combination produces more comprehensive metabolic intervention than any single or dual receptor approach: reduced appetite (GLP-1 and GIP), improved insulin sensitivity (GLP-1 and GIP), and increased energy expenditure with fat breakdown (glucagon). The preclinical and early clinical data show weight reduction outcomes that exceed the dual-agonist class.
For significant metabolic challenges, under close care.
Retatrutide is appropriate for patients who have a significant weight management objective and are being managed under close medical supervision. It may be a starting point for patients with substantial metabolic burden, or a next step for patients who have plateaued on GLP-1 or dual-agonist therapy.
This is not a casual protocol. The triple receptor mechanism produces stronger effects and requires attentive monitoring. We're selective about patient selection and thorough in our initial evaluation.
- Substantial weight reduction
- Increased energy expenditure
- Enhanced fat breakdown and oxidation
- Improved metabolic flexibility
- Advanced cardiometabolic improvements
- Post-GLP-1 plateau option
Careful, gradual, supervised.
Titration is slower and more careful than standard GLP-1 protocols. The triple mechanism produces stronger metabolic and GI effects, and the adjustment period requires patience. We start at the lowest dose and move deliberately.
Monitoring includes metabolic labs, cardiovascular markers, and regular clinical check-ins. This is a protocol where staying in close contact with the prescribing physician isn't optional — it's how we keep the outcomes positive.
| Phase | Approach | Monitoring |
|---|---|---|
| Initial | Low dose, slow titration | Metabolic labs, vitals |
| Adjustment | 4-week intervals | GI tolerance, weight, glucose |
| Maintenance | Individualized dose | Quarterly labs minimum |
| Review | Every 3–6 months | Full panel + clinical assessment |
What you should know
GI side effects are more pronounced than with semaglutide alone — nausea, vomiting, and diarrhea during titration are the primary concerns. Managing the titration rate is the most effective mitigation strategy.
The glucagon receptor component adds considerations around blood pressure and heart rate, which are monitored as part of the protocol. As with all GLP-1 class medications, thyroid and pancreatic contraindications apply.
Common questions about Retatrutide
Retatrutide is in Phase 3 clinical trials at the pharmaceutical level. Compounded retatrutide is available through licensed 503B compounding pharmacies for clinical use. This is a standard pathway for emerging therapeutics in functional medicine.
Early clinical data suggests greater mean weight reduction with retatrutide. The experience is also more intensive — stronger GI effects during titration, more aggressive metabolic response. It's a more powerful tool that requires more careful management.
Depends on the patient. For someone with substantial metabolic challenges, it may be the appropriate starting protocol. For others, starting with semaglutide or tirzepatide and escalating makes more sense. We discuss this during the initial evaluation.
We review your labs, goals, and health history before recommending any protocol. Available in-person in St. Louis or via secure telehealth.
📅 Request a Consultation →